Buyback Update
Zydus Lifesciences Revises Buyback Price Upward to ₹1,260 Per Share
NSE
zyduslife
BSE
532321
Zydus Lifesciences Limited has approved revisions to its ongoing equity share buyback program. The company increased the buyback price from ₹1,150 per share to ₹1,260 per share while reducing the maximum number of shares to be bought back from 95.65 lakh shares to 87.30 lakh shares. The aggregate buyback size remains unchanged at ₹1,100 crore. The revised buyback represents up to 0.87% of the company’s paid-up equity share capital.
PRICE-SENSITIVE TRIGGER
Event: Revision in Buyback Price and Share Quantity
Type: Buyback Update
Impact: Positive
Immediate Effect: The company increased the buyback price by 9.6%, signaling management confidence and enhancing shareholder payout attractiveness while maintaining the total buyback outlay at ₹1,100 crore.
Key Metrics:
- Revised Buyback Price: ₹1,260 per share
- Earlier Buyback Price: ₹1,150 per share
- Increase in Buyback Price: ₹110 per share (+9.6%)
- Total Buyback Size: ₹1,100 crore
- Previous Maximum Shares: 95,65,217 equity shares
- Revised Maximum Shares: 87,30,158 equity shares
- Face Value per Share: ₹1
- Maximum Equity Capital Covered: Up to 0.87% of paid-up share capital
Highlight:
- Zydus Lifesciences raised the buyback price by ₹110 per share while keeping the total buyback consideration unchanged at ₹1,100 crore, effectively improving shareholder realization.
What Happened ?
Zydus Lifesciences Limited informed exchanges that its Buyback Committee approved revisions to the company’s ongoing share buyback program during its meeting held on May 27, 2026.
The company increased the buyback price from ₹1,150 per equity share to ₹1,260 per equity share under the tender offer route.
Simultaneously, the maximum number of shares proposed to be bought back was reduced from 95,65,217 equity shares to 87,30,158 equity shares.
Despite the revision in share quantity, the overall buyback size remains unchanged at ₹1,100 crore.
The buyback pertains to fully paid-up equity shares having a face value of ₹1 each and is being conducted in accordance with SEBI Buyback Regulations and applicable provisions of the Companies Act, 2013.
The company also stated that an addendum to the public announcement regarding the revised terms will be published in newspapers and made available on the websites of the company, manager to the buyback, and SEBI.
Key Details
Buyback Revision Details:
- Buyback price revised upward to ₹1,260 per share from ₹1,150 per share.
- Total buyback consideration remains capped at ₹1,100 crore.
- Maximum buyback shares reduced to 87.30 lakh shares from 95.65 lakh shares.
- Revised buyback size represents up to 0.87% of paid-up equity share capital.
- Buyback will continue through the tender offer route.
- Equity shares carry a face value of ₹1 each.
- Buyback Committee approved revised terms on May 27, 2026.
- Addendum to public announcement will be published across designated newspapers and websites.
Note:
- The revised pricing structure improves shareholder exit value while maintaining disciplined capital allocation through a fixed aggregate buyback outlay.
Risk Analysis
Summary:
- While the revised buyback enhances shareholder value perception, execution and participation dynamics may still influence the final impact on earnings metrics and market response.
Key Risks:
- Reduced share quantity limits the total number of shares eligible for acceptance.
- Tender participation ratio may vary depending on shareholder response.
- Buyback completion remains subject to regulatory timelines and procedural compliance.
- Higher buyback price could influence short-term stock volatility.
- Limited equity reduction may moderate EPS accretion impact.
Worst Case Scenario:
- If market prices move materially above the revised buyback price or participation levels become excessively high, investor acceptance ratios could decline significantly.
Risk Level: Low
Company Commentary
- The Buyback Committee approved an increase in buyback price to ₹1,260 per share.
- The company reduced the maximum number of shares proposed for repurchase to 87.30 lakh shares.
- Total buyback consideration remains unchanged at ₹1,100 crore.
- Zydus Lifesciences stated that an addendum to the public announcement will be published in newspapers and uploaded on relevant websites during the buyback period.
- The buyback continues to be undertaken under SEBI Buyback Regulations and applicable laws.
Official Exchange Filing: Zydus Lifesciences Limited